Ahmed Samar A, Luu Vy T, Nsuga Teresa C Oyono, Burgos Steven E, Kreys Eugene, Arquiette Jered, Lenhard Justin R
Department of Clinical and Administrative Sciences, California Northstate University College of Pharmacy, Elk Grove, CA 95757, USA.
Department of Pharmacy, San Joaquin General Hospital, French Camp, CA 95231, USA.
Antibiotics (Basel). 2025 Jun 11;14(6):597. doi: 10.3390/antibiotics14060597.
: The optimal therapy for polymicrobial wound infections is poorly defined. We sought to characterize the ability of linezolid to combat mixed cultures of and . : The antistaphylococcal activity of linezolid was assessed in 24-h time-killing experiments that used and isolated from polymicrobial wound infections. Clindamycin was also evaluated as a comparator. A Hill-type mathematical model was used to assess the maximum killing of (E). The ability of linezolid to potentiate the activity of host defense peptides against was evaluated using LL-37. : In the presence of , the E of linezolid decreased in 5/9 co-culture experiments and increased in 4/9 co-culture experiments in comparison to linezolid against alone. The potency of linezolid was not significantly impacted by the presence of . In comparison, the maximal killing achieved by clindamycin decreased in eight out of nine experiments, and somewhat paradoxically, the potency increased in nine out of nine experiments. In the host defense peptide assay, the supratherapeutic linezolid concentration of 64 mg/L did not significantly enhance the killing of the LL-37 peptides ( ≥ 0.121), but the concentration of linezolid was significantly associated with the killing of one of three isolates ( = 0.005). : had a minimal impact on the antistaphylococcal activity of linezolid in comparison to clindamycin. Linezolid did not exert a consistent ability to enhance the antipseudomonal activity of host defense peptides. These data may help inform antimicrobial selection during polymicrobial wound infections.
多种微生物伤口感染的最佳治疗方法尚不明确。我们试图描述利奈唑胺对抗[具体细菌1]和[具体细菌2]混合培养物的能力。：在24小时杀菌实验中评估了利奈唑胺对从多种微生物伤口感染中分离出的[具体细菌1]和[具体细菌2]的抗葡萄球菌活性。还将克林霉素作为对照进行了评估。使用希尔型数学模型评估[具体细菌1]的最大杀灭率（E）。使用LL-37评估了利奈唑胺增强宿主防御肽对[具体细菌2]活性的能力。：与单独使用利奈唑胺对抗[具体细菌1]相比，在5/9的共培养实验中，利奈唑胺对[具体细菌1]的E降低，在4/9的共培养实验中升高。[具体细菌2]的存在对利奈唑胺的效力没有显著影响。相比之下，在9个实验中的8个实验中，克林霉素实现的最大[具体细菌1]杀灭率降低，且有点矛盾的是，在9个实验中的9个实验中效力增加。在宿主防御肽试验中，64mg/L的超治疗剂量利奈唑胺浓度并未显著增强LL-37肽的杀灭率（P≥0.121），但利奈唑胺浓度与三种[具体细菌2]分离株之一的杀灭率显著相关（P = 0.005）。：与克林霉素相比，[具体细菌2]对利奈唑胺的抗葡萄球菌活性影响最小。利奈唑胺没有表现出一致的增强宿主防御肽抗假单胞菌活性的能力。这些数据可能有助于为多种微生物伤口感染期间的抗菌药物选择提供参考。
